Physician profile
Simone Beattie
NPI 1326680125
$6,754.54
in general payments reported to CMS, 2019-2025
32 companies · $82.67 in 2025
The $82.67 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,408 · 2023: $3,662 · 2024: $1,602 · 2025: $82.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,236 · Travel and Lodging: $943 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,236.10 |
| Travel and Lodging | $942.85 |
| Education | $167.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,396.31 | 2022-2023 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,062.18 | 2022-2024 | Fasenra, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $508.11 | 2022-2024 | Dupixent |
| Genzyme Corporation | $466.57 | 2022-2024 | |
| Grifols USA, LLC | $451.78 | 2022-2024 | Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $442.90 | 2022-2024 | Nucala, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $303.06 | 2022-2023 | |
| Abbvie INC. | $251.54 | 2022-2025 | |
| Harmony Biosciences LLC | $250.49 | 2022-2024 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.99 | 2022-2023 | Ofev |
| United Therapeutics Corporation | $147.74 | 2023 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals US, INC. | $142.18 | 2023-2024 | Opsumit, Uptravi |
| Baxter Healthcare | $140.73 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Genentech USA, INC. | $83.68 | 2024 | Xolair |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.26 | 2022-2024 | Glassia |
| Novartis Pharmaceuticals Corporation | $81.03 | 2022-2024 | |
| Amgen INC. | $78.92 | 2023-2024 | Tezspire |
| Mylan Specialty L.P. | $65.29 | 2023 | Yupelri |
| Astellas Pharma US INC | $61.87 | 2022-2023 | Cresemba |
| Merck Sharp & Dohme LLC | $59.49 | 2023-2024 | Zerbaxa, Recarbrio |
| Electromed, INC. | $55.48 | 2023-2024 | Smartvest |
| Alexion Pharmaceuticals, INC. | $50.79 | 2023 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $46.18 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $43.29 | 2024 | Lumryz |
| Boston Scientific Corporation | $35.09 | 2025 | Watchman Flx |
| Axsome Therapeutics, INC. | $23.51 | 2024 | Sunosi |
| Bard Peripheral Vascular, INC. | $20.65 | 2023 | |
| Pharming Healthcare, INC. | $19.65 | 2023 | Ruconest |
| Ani Pharmaceuticals, INC. | $19.15 | 2023 | Purified Cortrophin Gel |
| Teva Pharmaceuticals USA, INC. | $16.02 | 2022 | |
| Philips North America LLC | $15.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Beattie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.